AIM IMMUNOTECH INC. Increase (Decrease) in Accounts Receivable
AIM IMMUNOTECH INC. (AIM) reported Increase (Decrease) in Accounts Receivable of -$1.18 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-03-27
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was -$3.00K, a 100.25% decline year-over-year.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $0.00.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $3.00K.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was -$1.18M.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for fiscal 2024 was -$1.18M.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for fiscal 2023 was -$492.00K, a 1505.71% decline from fiscal 2022.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for fiscal 2022 was $35.00K.
- AIM IMMUNOTECH INC. increase (decrease) in accounts receivable for fiscal 2021 was -$34.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$3.00K derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | -$1.18M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $3.00K derived: sum of 2 quarters · filed 2025-11-17 | -$1.18M 10-Q · filed 2025-11-17 | $3.00K derived: sum of 4 quarters · filed 2025-11-17 | |
| 2024-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.18M 10-Q · filed 2025-08-14 | $3.00K derived: sum of 3 quarters · filed 2025-08-14 | $3.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$1.18M 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.18M derived: sum of 2 quarters · filed 2025-03-27 | -$492.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.68M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$1.68M 10-Q · filed 2024-08-14 | ||||
| 2022-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $35.00K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$1.64M 10-Q · filed 2023-11-14 | ||||
| 2021-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$28.00K derived: sum of 2 quarters · filed 2023-03-31 | -$34.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$6.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$6.00K 10-Q · filed 2022-08-15 | ||||
| 2020-12-31 | -$22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$36.00K derived: sum of 2 quarters · filed 2022-03-31 | -$42.00K derived: sum of 3 quarters · filed 2022-03-31 | -$40.00K 10-K · filed 2022-03-31 | $40.00K 10-K · filed 2021-03-31 |
| 2020-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$20.00K derived: sum of 2 quarters · filed 2021-11-15 | -$18.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$4.00K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $2.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $191.00K 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.06M derived: sum of 2 quarters · filed 2019-04-01 | $1.06M derived: sum of 3 quarters · filed 2019-04-01 | $1.07M 10-K · filed 2019-04-01 | |
| 2018-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$2.00K derived: sum of 2 quarters · filed 2018-11-14 | $4.00K 10-Q · filed 2018-11-14 | -$14.00K derived: sum of 4 quarters · filed 2019-04-01 | |
| 2018-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $11.00K 10-Q · filed 2018-08-14 | -$7.00K derived: sum of 3 quarters · filed 2019-04-01 | -$63.00K derived: sum of 4 quarters · filed 2019-04-01 | |
| 2018-03-31 | $6.00K 10-Q · filed 2018-05-15 | -$12.00K derived: sum of 2 quarters · filed 2019-04-01 | -$68.00K derived: sum of 3 quarters · filed 2019-04-01 | -$11.00K derived: sum of 4 quarters · filed 2019-04-01 | |
| 2017-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$74.00K derived: sum of 2 quarters · filed 2019-04-01 | -$17.00K derived: sum of 3 quarters · filed 2019-04-01 | $24.00K 10-K · filed 2019-04-01 | |
| 2017-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $1.00K derived: sum of 2 quarters · filed 2018-11-14 | $42.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $98.00K 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | $41.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |